Roche Says Actemra-Remdesivir Trial Fails to Cut Hospital Stays

ZURICH (Reuters) – Swiss drugmaker Roche said on Thursday adding its drug Actemra to Gilead Sciences’ Veklury medication, also called remdesivir, did not reduce hospital stays for patients with severe COVID-19 pneumonia. Roche’s anti-inflammatory Actemra combined with Veklury, Gilead’s antiviral drug, failed to reduce hospitalisation durations in the REMDACTA trial, which compared the cocktail with […]

Novartis’s Bid to Repurpose Inflammation Drug Ilaris Takes Another Hit

ZURICH (Reuters) – Novartis’s uphill struggle to re-purpose its inflammation drug Ilaris took another hit when the Swiss drugmaker said on Tuesday that the medicine failed to boost overall survival in lung cancer patients in a late-stage trial. The drug, known generically as canakinumab and long approved to treat juvenile arthritis and rare Mediterranean fever, […]